Skip to main content
. Author manuscript; available in PMC: 2020 Apr 24.
Published in final edited form as: Oncogene. 2018 Sep 3;38(5):716–730. doi: 10.1038/s41388-018-0461-3

Figure 7. Antagonizing the androgen axis increases CD105 and SFRP1 expression with elevated neuroendocrine differentiation.

Figure 7.

Diagram shows the evolution of prostate cancer stroma and epithelia. Castrate sensitive prostate cancer epithelia (blue top layer of cells) and stromal fibroblasts (bottom elongated layer of gray and CD105+ red cells) are both initially heterogeneous. After treatment with ADT, the epithelia and stroma express more CD105 (red). ADT induces SFRP1 secretion by fibroblasts that signal to the adjacent epithelia to induce neuroendocrine differentiation. The combined treatment with ADT and CD105 inhibition via TRC105 resulted in SFRP1 downregulation and reduced epithelial neuroendocrine differentiation in promoting castrate sensitivity.